Filing Flows › Stoke Therapeutics (STOK) › Q3 2026 › vs Q2 2026
Stoke Therapeutics (STOK) Q3 2026 vs Q2 2026 (quarter over quarter)
Stoke Therapeutics's revenue rose $1.9M (+21%) from $9.3M in Q2 2026 to $11.3M in Q3 2026.
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $11.3M | $9.3M | $1.9M | +21% |
| Other income, net | $3.7M | $3.8M | −$140K | -4% |
| Net loss | $73.6M | $61.6M | $12.0M | +20% |
| Costs & expenses | $88.6M | $74.8M | $13.8M | +18% |
| Operating costs | $88.6M | $74.8M | $13.8M | +18% |
| Research & development | $59.8M | $49.5M | $10.3M | +21% |
| SG&A | $28.7M | $25.3M | $3.5M | +14% |
| Operating cash sources | $74.2M | $67.8M | $6.3M | +9% |
| Depreciation | $455K | $458K | −$3K | -0.7% |
| Share-based compensation | $11.0M | $10.8M | $231K | +2% |
| Cash used in operations | $62.7M | $56.6M | $6.1M | +11% |
| Net loss absorbed | $73.6M | $61.6M | $12.0M | +20% |
| Working capital & other | $530K | $6.2M | −$5.7M | -91% |
Questions
How much did Stoke Therapeutics's revenue grow quarter over quarter in Q3 2026?
Stoke Therapeutics's revenue rose $1.9M (+21%) from $9.3M in Q2 2026 to $11.3M in Q3 2026.